Last reviewed · How we verify
Aliqopa (COPANLISIB)
Aliqopa (COPANLISIB) is a small molecule kinase inhibitor developed by Bayer Healthcare, targeting the phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. It was FDA-approved in 2017 for the treatment of follicular lymphoma. Aliqopa is a patented medication with no generic manufacturers available. Key safety considerations include its potential for severe side effects such as neutropenia and thrombocytopenia. It has a half-life of approximately 25.2 hours.
At a glance
| Generic name | COPANLISIB |
|---|---|
| Sponsor | Bayer |
| Drug class | Kinase Inhibitor |
| Target | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
- Follicular lymphoma
Common side effects
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1,PHASE2)
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) (PHASE2)
- Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) (PHASE2)
- Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma (PHASE1)
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (PHASE1,PHASE2)
- Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |